These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 6232993)

  • 41. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study.
    Ross HJ; Gullestad L; Pak J; Slauson S; Valantine HA; Hunt SA
    J Heart Lung Transplant; 1997 Feb; 16(2):179-89. PubMed ID: 9059929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced infection in cardiac transplant recipients.
    Dresdale AR; Drusin RE; Lamb J; Smith CR; Reemtsma K; Rose EA
    Circulation; 1985 Sep; 72(3 Pt 2):II237-40. PubMed ID: 3896557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Late acute cardiac allograft rejection: new therapeutic options?
    Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH
    Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triple-drug immunosuppression for heart transplantation in infants and children.
    Brown JW; Turrentine MW; Kesler KA; Mahomed Y; Darragh R; Evans K; Thompson L; Caldwell R
    J Heart Lung Transplant; 1993; 12(6 Pt 2):S265-74. PubMed ID: 8312346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.
    McNamara D; Di Salvo T; Mathier M; Keck S; Semigran M; Dec GW
    J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-dose cyclosporine treatment fails to prevent coronary luminal narrowing after heart transplantation.
    Vassalli G; Kaski JC; Tousoulis D; Kiowski W; Turina M; Follath F; Gallino A
    J Heart Lung Transplant; 1996 Jun; 15(6):612-9. PubMed ID: 8794036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period?
    Mahalati K; Lawen J; Kiberd B; Belitsky P
    J Urol; 2000 Jan; 163(1):37-41. PubMed ID: 10604309
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation.
    Glanville AR; Aboyoun CL; Morton JM; Plit M; Malouf MA
    J Heart Lung Transplant; 2006 Aug; 25(8):928-34. PubMed ID: 16890113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome of renal transplantation subsequent to liver, heart, or lung transplantation.
    Tarnow H; Herlenius G; Friman S; Olausson M; Nordén G; Felldin M; Bäckman L
    Transplant Proc; 2006 Oct; 38(8):2649-50. PubMed ID: 17098027
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation.
    Pedrosa MC; Rohrer RM; Kaplan MM
    Clin Transplant; 1995 Aug; 9(4):322-5. PubMed ID: 7579741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytoimmunologic monitoring after heart and heart-lung transplantation.
    May RM; Cooper DK; Du Toit ED; Reichart B
    J Heart Transplant; 1990; 9(2):133-5. PubMed ID: 2319372
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclosporine: a new immunosuppressive agent for organ transplantation.
    Cohen DJ; Loertscher R; Rubin MF; Tilney NL; Carpenter CB; Strom TB
    Ann Intern Med; 1984 Nov; 101(5):667-82. PubMed ID: 6385799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of toxic side effects of cyclosporine in heart transplantation.
    Schüler S; Warnecke H; Hetzer R
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2518-21. PubMed ID: 3547936
    [No Abstract]   [Full Text] [Related]  

  • 54. [Follow-up of heart transplants].
    Mosseri M; Admon D; Yarom R; Rosenheck S; Gotsman MS
    Harefuah; 1989 Jan; 116(1):17-21. PubMed ID: 2651234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Significance of asymptomatic biliary tract disease in heart transplant recipients.
    Girardet RE; Rosenbloom P; DeWeese BM; Masri ZH; Attum AA; Barbie RN; Yared SF; Lusk RA; Lansing AM
    J Heart Transplant; 1989; 8(5):391-9. PubMed ID: 2795282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurologic complications of cardiac transplantation.
    Andrews BT; Hershon JJ; Calanchini P; Avery GJ; Hill JD
    West J Med; 1990 Aug; 153(2):146-8. PubMed ID: 2219870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term effects of cyclosporine-based immunosuppression in cardiac transplantation: the Loyola experience.
    Costanzo-Nordin MR; Grady KL; Johnson MR; Winters GL; Ventura HO; Pifarré R
    Transplant Proc; 1990 Jun; 22(3 Suppl 1):6-11. PubMed ID: 2349737
    [No Abstract]   [Full Text] [Related]  

  • 58. Diffusing lung capacity and cyclosporine in patients with heart transplants.
    Casan P; Sanchis J; Cladellas M; Amengual MJ; Caralps JM
    J Heart Transplant; 1987; 6(1):54-6. PubMed ID: 3302187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypertension following orthotopic cardiac transplantation.
    Shapiro AP; Rutan GH; Thompson ME; Nigalye RL
    Cardiovasc Clin; 1990; 20(2):179-88. PubMed ID: 2404598
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone.
    Sibley RK; Rynasiewicz J; Ferguson RM; Fryd D; Sutherland DE; Simmons RL; Najarian JS
    Surgery; 1983 Aug; 94(2):225-34. PubMed ID: 6348988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.